GlobeNewswire·Nov 10, 2026, 7:30 AM ET

Cerenome Appoints Director Ron Andrews as Chief Business Officer

CNSY

Cerenome, Inc. (Nasdaq: CNSY) announced the appointment of Ron "Ronnie" Andrews as its new Chief Business Officer, a newly created position.
Mr. Andrews will continue serving on the Company's Board of Directors while focusing on business development, commercial strategy, and expanding adoption of the CNSide® Diagnostics platform.
He brings over 35 years of diagnostics industry experience, having helped companies raise more than $600 million in capital & contributed to strategic exits totaling over $15 billion.
Prior roles include founder of The Bethesda Group Advisors, CEO & Vice Chairman of Clarient (acquired by GE Healthcare for $587 million), & leadership at Life Technologies, Thermo Fisher Scientific, & Oncocyte.
Mr. Andrews currently holds board positions with Agendia, SimBioSys, SMi Systems, & Dxcover Ltd, & serves as a Trustee at Wofford College.
Cerenome operates as a CNS oncology company integrating diagnostics, therapeutics, & artificial intelligence to improve outcomes for patients with central nervous system cancers.
The Company's lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is currently under clinical evaluation for leptomeningeal metastases, recurrent glioblastoma, & pediatric brain cancers.
The CNSide® CSF diagnostics platform combines cellular & molecular testing to support detection, characterization, & longitudinal assessment of CNS cancers.
This press release includes forward-looking statements regarding clinical trials, commercialization timelines, & revenue expectations.

Company: Cerenome, Inc.
Keywords: Nasdaq:CNSY, Cerenome, Inc.